Deepinder Goyal, the founder and CEO of Zomato parent Eternal, is making a serious push into longevity medicine. His health and wellness startup Temple has acquired London-based Longevous, a company focused on preventive health and lifespan optimization, according to Economic Times reporting on the deal. Financial terms were not disclosed, but the move signals that Temple is no longer just a domestic wellness play — it’s reaching into the global longevity science market. For anyone tracking how India’s tech founders are spending their next act, this is a notable data point.
Temple was founded by Goyal with a stated mission to help people live longer, healthier lives through data-driven, preventive approaches to medicine. The startup sits at an intersection that’s drawing serious capital globally — health intelligence systems are converging faster than most traditional healthcare players anticipated. Longevous, operating out of London, brought expertise in longevity protocols and personalized health interventions to the table, making it a strategically coherent target for Temple’s ambitions.
Why a London Acquisition Makes Strategic Sense
The UK has quietly become one of the more active hubs for longevity science, with a cluster of startups, research institutions, and clinics building around the idea that aging is a treatable condition rather than an inevitability. By acquiring Longevous rather than building from scratch, Temple gets immediate access to established protocols, a scientific team, and credibility within European health circles — markets that are notoriously difficult to crack cold.
Goyal has been public about his personal investment in health optimization, and Temple reflects that obsession at a company level. The acquisition of a London outfit also gives Temple an international footprint at a time when the global longevity market is heating up fast. Investors have poured billions into the sector over the past three years, betting that advances in biomarkers, metabolic health monitoring, and targeted supplementation can meaningfully extend healthspan — the years a person lives in good health, not just alive.
Temple’s Bigger Play in Preventive Health
What makes this acquisition worth watching is not just the geography — it’s the model Temple appears to be building toward. Rather than a single clinic or a generic wellness app, Temple seems to be assembling capabilities across diagnostics, data science, and now longevity science protocols. Longevous adds another layer to that stack. This kind of roll-up approach in health tech mirrors what companies like Hims and Hers executed in the consumer health space, but with a sharper scientific edge.
The deal also underscores a broader pattern among India’s most prominent tech founders diversifying into health and life sciences. Goyal’s profile — high-visibility, data-obsessed, with access to deep networks across tech and capital — is exactly the kind of operator that can pull together a credible longevity brand. Compare this to adjacent tech sectors, where founders are increasingly using M&A to accelerate platform assembly rather than waiting on organic growth. Temple appears to be following precisely that playbook — and the Longevous deal suggests it’s moving faster than most people realized.
